Annikka Weissferdt Selected Research

Neoplasms (Cancer)

11/2022	Surgical outcomes after neoadjuvant nivolumab or nivolumab with ipilimumab in patients with non-small cell lung cancer.
1/2022	Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes.
1/2022	Management of Bronchial Adenoma/Ciliated Muconodular Papillary Tumor with Definitive Stereotactic Body Radiation Therapy (SBRT): A Case Report.
7/2021	CD73 expression defines immune, molecular, and clinicopathological subgroups of lung adenocarcinoma.
1/2021	Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer.
1/2021	Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial.
1/2021	Neoadjuvant Chemotherapy Increases Cytotoxic T Cell, Tissue Resident Memory T Cell, and B Cell Infiltration in Resectable NSCLC.
1/2021	Controversies and challenges in the pathologic examination of lung resection specimens after neoadjuvant treatment.
1/2021	Evaluation of Pathologic Response in Lymph Nodes of Patients With Lung Cancer Receiving Neoadjuvant Chemotherapy.
8/2020	18F-fluorodeoxyglucose positron emission tomography correlates with tumor immunometabolic phenotypes in resected lung cancer.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Annikka Weissferdt Research Topics

Disease

42	Neoplasms (Cancer) 11/2022 - 05/2006
12	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 11/2022 - 10/2017
8	Thymoma (Thymic Carcinoma) 01/2017 - 07/2011
6	Lung Neoplasms (Lung Cancer) 01/2021 - 10/2017
4	Adenocarcinoma 03/2020 - 06/2015
3	Neuroendocrine Carcinoma 04/2015 - 01/2013
3	Seminoma 03/2015 - 10/2014
2	Adenocarcinoma of Lung 07/2021 - 06/2015
2	Granuloma 01/2021 - 08/2013
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2018 - 09/2012
2	Glandular and Epithelial Neoplasms (Neoplasms, Glandular) 01/2017 - 09/2011
2	Carcinoma (Carcinomatosis) 01/2017 - 03/2016
1	Adenoma (Adenomas) 01/2022
1	Inflammation (Inflammations) 07/2021
1	Pathologic Complete Response 01/2021
1	Disease Progression 01/2021
1	Synovial Sarcoma (Synovioma) 01/2020
1	Infections 02/2018
1	Exanthema (Rash) 02/2018
1	Sepsis (Septicemia) 02/2018
1	Agranulocytosis (Granulocytopenia) 02/2018
1	Hypokalemia 02/2018
1	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 02/2018
1	Testicular Teratoma 01/2018
1	Osteosarcoma (Osteogenic Sarcoma) 01/2018
1	Primitive Neuroectodermal Tumors (PNET) 01/2018
1	Meningioma (Meningiomas) 12/2015
1	Mucinous Adenocarcinoma (Mucinous Carcinoma) 06/2015
1	Adult T-Cell Leukemia-Lymphoma (Leukemia Lymphoma, T Cell, Acute, HTLV I Associated) 03/2015
1	Melanoma (Melanoma, Malignant) 03/2015
1	Hyperplasia 02/2015
1	Paraganglioma (Paragangliomas) 12/2014
1	Neuroendocrine Tumors (Neuroendocrine Tumor) 12/2014
1	Large Cell Carcinoma 07/2014
1	Neurilemmoma (Schwannoma) 11/2013
1	Necrosis 08/2013

Drug/Important Bio-Agent (IBA)

7	Biomarkers (Surrogate Marker)IBA 07/2021 - 01/2017
6	AntibodiesIBA 01/2022 - 07/2011
6	CAM 5.2 antigenIBA 01/2019 - 06/2013
6	Keratin-5 (Keratin 5)IBA 07/2016 - 07/2011
5	SynaptophysinIBA 01/2018 - 07/2011
5	Keratins (Keratin)IBA 01/2017 - 07/2012
5	Biological ProductsIBA 03/2016 - 08/2010
4	Immune Checkpoint InhibitorsIBA 11/2022 - 03/2020
4	LigandsIBA 01/2018 - 09/2012
4	Thyroid Nuclear Factor 1IBA 01/2017 - 06/2012
4	Calbindin 2IBA 01/2017 - 07/2011
3	Proteins (Proteins, Gene)FDA Link 09/2012 - 02/2011
2	IpilimumabIBA 11/2022 - 01/2021
2	NivolumabIBA 11/2022 - 01/2021
2	B7-H1 AntigenIBA 07/2021 - 01/2020
2	Cisplatin (Platino)FDA LinkGeneric 01/2020 - 02/2018
2	Docetaxel (Taxotere)FDA Link 01/2020 - 02/2018
2	GlypicansIBA 01/2019 - 03/2015
2	Formaldehyde (Formol)FDA Link 01/2019 - 01/2018
2	ParaffinIBA 01/2019 - 01/2018
2	ChromograninsIBA 01/2018 - 07/2011
2	MucinsIBA 01/2018 - 06/2015
2	Chromogranin AIBA 03/2016 - 12/2014
2	Transcription Factors (Transcription Factor)IBA 12/2014 - 09/2011
2	Inhibins (Inhibin)IBA 01/2014 - 06/2013
2	Mucin-1 (CA 15-3 Antigen)IBA 08/2013 - 07/2011
2	VimentinIBA 04/2013 - 12/2012
1	InterleukinsIBA 01/2022
1	urelumabIBA 01/2022
1	Interleukin-2 (IL2)IBA 01/2022
1	EnzymesIBA 07/2021
1	Adenosine (Adenocard)FDA LinkGeneric 07/2021
1	Phenobarbital (Luminal)FDA Link 07/2021
1	Pharmaceutical PreparationsIBA 01/2021
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2021
1	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 08/2020
1	Indicators and Reagents (Reagents)IBA 08/2020
1	nintedanibIBA 01/2020
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 02/2018
1	PlatinumIBA 02/2018
1	RNA (Ribonucleic Acid)IBA 01/2018
1	DesmocollinsIBA 01/2017
1	DNA Nucleotidylexotransferase (Terminal Deoxynucleotidyl Transferase)IBA 07/2016
1	Surface-Active Agents (Surfactants)IBA 06/2015
1	Colloids (Colloid)IBA 06/2015
1	Adrenocorticotropic Hormone (ACTH)FDA Link 04/2015
1	AntigensIBA 03/2015
1	Carrier Proteins (Binding Protein)IBA 03/2015
1	Transcription Factor 3IBA 03/2015
1	Transcription Factor 4IBA 03/2015
1	Neoplasm Antigens (Tumor Antigens)IBA 02/2015
1	germ-cell AP isoenzymeIBA 10/2014
1	CholesterolIBA 08/2013
1	Carcinoembryonic AntigenIBA 08/2013

Therapy/Procedure

14	Therapeutics 01/2021 - 09/2011
7	Neoadjuvant Therapy 01/2021 - 08/2013
6	Drug Therapy (Chemotherapy) 11/2022 - 05/2006
4	Immunotherapy 01/2022 - 01/2018
1	Radiotherapy 01/2022
1	Perioperative Period 02/2018
1	Combination Drug Therapy (Combination Chemotherapy) 01/2018
1	Thymectomy 03/2016
1	Thoracotomy 10/2014
1	Sagittal Split Ramus Osteotomy 11/2013